SCHEMBL524475

SCHEMBL524475

NCCCNCCCCNC(=O)C(=O)NCCCCCCCCNC=NN

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 3/20 0.44
CA12 O43570 2/20 0.41
F13A1 P00488 2/20 0.41
CA2 P00918 2/20 0.41
CYP1A2 P05177 2/20 0.41
ALOX15 P16050 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
THPO P40225 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
MEN1 O00255 1/20 0.41
CYP2C19 P33261 1/20 0.41
CASP2 P42575 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL525321 1.00 PAOX (0.44) PAOXCA12F13A1CA2CYP1A2
Trifluoroacetic Acid SCHEMBL9178322 0.91 HDAC6 (0.47) PAOXCA12CA2CA4CA6
Trifluoroacetic Acid SCHEMBL9173135 0.91 HDAC6 (0.47) PAOXCA12CA2CA4CA6
SCHEMBL524787 0.89 PAOX (0.42) PAOXCA12F13A1CA2CYP1A2
SCHEMBL525138 0.89 PAOX (0.42) PAOXCA12F13A1CA2CYP1A2
Hydrochloric Acid SCHEMBL9173284 0.88 PAOX (0.41) PAOXCA12F13A1CA2CYP1A2
SCHEMBL524487 0.85 GRIA1 (0.41) PAOXHDAC6
SCHEMBL524329 0.85 GRIA1 (0.41) PAOXHDAC6
SCHEMBL523782 0.84 GRIA1 (0.40) PAOXHDAC6
SCHEMBL525824 0.84 GRIA1 (0.40) PAOXHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190278-A1 Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases LABORATOIRES FOURNIER SA (FR) 2013-07-25 US disclosed
EP-2598131-A1 COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES Laboratoires Fournier S.A. (FR) 2013-06-05 EP disclosed
WO-2012013884-A1 COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES LABORATOIRES FOURNIER SA (FR) 2012-02-02 WO disclosed
EP-0600762-B1 Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants FOURNIER IND & SANTE (FR) 1996-07-10 EP disclosed
EP-0600762-A1 Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants FOURNIER INDUSTRIE ET SANTE (FR) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190278-A1 Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases TNF, NFKBIA, ALDH1A2 PAOX 1954/4885CA12 1403/4885F13A1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.